Floatz logo

FERUMOXTRAN 10

Rectal Neoplasms

Radboud University Medical CenterOtherPhase 3Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
39/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Rectal Neoplasms cohort.

View all 46

Same molecule, other indications

FERUMOXTRAN 10 is also rated in:

prostate cancerDormant
CCC
Indicative ·
54 / 100
View asset →
metastatic neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
urinary bladder carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →